罗格列酮对2型糖尿病患者血清抵抗素水平的影响

目的研究罗格列酮(ROS)对2型糖尿病患者血清抵抗素(Resistin)水平的影响。方法符合1999年WHO糖尿病诊断标准的初诊2型糖尿病患者38例,均给予口服ROS 4 mg,每日1次,总疗程4周,测定指标包括一般项目、血糖和血清胰岛素及抵抗素,以HOMA模型评价组织胰岛素敏感性。结果ROS治疗4周后,患者空腹血糖、血清胰岛素水平及胰岛素抵抗指数(HOMA-IR)明显降低(P<0.01或P<0.05),而体重指数(BMI)及腰臀比(WHR)明显增加(P<0.05);血清抵抗素水平前后比较差异无统计学意义(P>0.05)。Pearson相关性分析显示,2型糖尿病患者血清抵抗素水平与体重指数、腰臀比和HOMA-IR等无关(P>0.05)。结论ROS能显著降低2型糖尿病患者胰岛素抵抗程度,改善糖代谢,但对人血清抵抗素水平无明显影响。

Effect of rosiglitazone on resistin level in patients with type 2 diabetes

Objective To study the effect of rosiglitazone(ROS) on resistin level in patients with type 2 diabetes.Methods Thirty-eight patients with type 2 diabetes mellitus were recruited according to WHO criterion(1999).Self-pair trial was used and each patient was orally given ROS 4 mg each day for 4 weeks.Clinical routine and plasma glucose,insulin and resistin determination were performed.Insulin sensitivity was evaluated using homeostasis model assessment(HOMA) formula.Results Levels of fasting plasma glucose,insulin and HOMA-IR were significantly decreased(P<0.0l or P<0.05),whereas the values of BMI and WHR increased significantly(P<0.05)after 4 week ROS treatment.The levels of resistin before and after treatment had no significant difference.Notably,the level of serum resistin in patients with type 2 diabetes has no significant correlation with BMI,WHR and HOMA-IR(Pearson correlation analysis,P>0.05).Conclusion ROS can significantly reduce insulin resistance,improve the utilizing of plasma glucose,nevertheless has a little effect on level of resistin in patients with type 2 diabetes.